+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 0 - 65Years
All Genders
ID07254793

Pilot Study of Exercise-Mobilized Donor Lymphocyte Infusions to Prevent Leukemia Relapse After Allogeneic Hematopoietic Cell Transplantation

Led by University of Arizona · Updated on 2026-10-29

180

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are conducting the first human trial to study prophylactic DLI-X pro-DLI-X for preventing relapse after allogeneic hematopoietic cell transplantation HCT using matched sibling donors or haploidentical donors in patients with blood cancers like leukemia and lymphoma. This Phase 1 randomized study aims to evaluate whether pro-DLI-X can safely enhance immune cell-mediated graft-versus-leukemia effects while managing graft-versus-host disease GvHD. Participants will be randomly assigned to receive either exercise mobilized donor lymphocyte infusion pro-DLI-X or standard prophylactic donor lymphocyte infusion pro-DLI following their transplant. Both treatments are given through a central line in up to three increasing doses based on recipient weight and transplant type. The study compares the two approaches to see if exercise mobilization improves relapse prevention. During the study, participants will be monitored for graft-versus-host disease-free, relapse-free survival between 1 to 3 years after transplant. Researchers will assess safety and efficacy outcomes while tracking immune responses. The study includes adult patients up to age 65 with certain leukemias or lymphomas who have a suitable donor able to perform exercise sessions. Participation involves multiple doses and long-term follow-up to evaluate treatment effects and patient health.

CONDITIONS

Brief Title

Prophylactic DLI-X for Leukemia Relapse After HCT

Research Team

M

Michele Chu-Pilli

U

UACC IIT

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here